H.C. Wainwright analyst Brandon Folkes lowered the firm’s price target on CorMedix (CRMD) to $17 from $20 and keeps a Buy rating on the shares. The firm views the acquisition of Melinta Therapeutics as neutral.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRMD:
- CorMedix Inc. Reports Strong Q2 2025 Results
- M&A News: CorMedix Stock (CRMD) Plunges 11% Despite $300M Melinta Deal
- Cormedix’s Strategic Growth Potential Boosted by Melinta Therapeutics Acquisition
- CorMedix Announces Merger Agreement with Melinta Therapeutics
- CorMedix sees FY25 pro forma revenue $305M-$335M